Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab step-down strategy to maintain remission in atopic dermatitis
2022-501179-23-00Phase 4Completed
- Sponsor
- CHU de Nantes
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of dupilumab in atopic dermatitis (AD) (2 arms), sponsored by CHU de Nantes. Primary endpoint: Area under the curve of Atopic Dermatitis Control Tool score over 1 year. Started Mar 2023; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2022-501179-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501179-23-00.